PODCAST · health
The Uromigos
by The Uromigos
Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Episodes
-
Episode 520: ESMO 2026 Preview
Silke, Brian and Tom preview the major data to be presented at ESMO 2026
-
Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?
Shilpa Gupta joins us to discuss an X poll revealing equipoise about treatment approaches to resected high-risk upper tract urothelial cancer (UTUC).
-
Episode 518: PSMAddition in Clinical Practice
Rob Dreicer joins the show to discuss the FDA approval of Lutetium Lu 177 in the mHSPC space and how to contextualize the benefit/risk
-
Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates
Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.
-
Episode 516: The Influence of Hypoxia on Response and Resistance in RCC
Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypoxia on immune response in RCC.
-
Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala
Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.
-
Episode 514: Artificial Intelligence in Cancer Drug Development
Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.
-
Episode 513: Trials and Tribulations of Investigator-initiated Research
Bishoy Faltas joins Brian and Tom to discuss his IIT in bladder cancer. The intended discussion of the trials turned into an insightful discussion on the challenges and learning opportunities of IITs.
-
Episode 512: ENZA-P Nature Medicine translational data
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
-
Episode 510: ADCs in Prostate Cancer
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.
-
Episode 509: ASCO 2026 Review
This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology.
-
Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
-
Episode 507: ASCO 2026 - TALAPRO-3
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.
-
Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?
This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and innovative approaches to assessment. Experts discuss the limitations of current...
-
Episode 505 : ASCO 2026 - RAMPART
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
-
Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer
This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer...
-
Episode 499: APCCC 2026 - Radioligands in Prostate Cancer
This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.
-
Episode 503: ASCO 2026 Preview
Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026
-
Episode 502: AUA 2026 and FDA bladder cancer meeting
In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on...
-
Episode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer
Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.
-
Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)
Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior...
-
Episode 499: APCCC 2026 - Radioligands
This session from APCCC 2026 features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in current practices, challenges, and future directions in radiopharmaceuticals.
-
Episode 498: APCCC 2026 - mCRPC
This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-driven therapy, and emerging treatment options.
-
Episode 497: Reflections on the capivasertib ODAC
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.
-
Episode 496: APCCC 2026 - mHSPC Landscape
Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
-
Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer
This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment decisions.
-
Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist
Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.
-
Episode 493: The Role of Chemotherapy in mHSPC
In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights shared during a recent conversation with Dr. Deepak Kilari, a GU Medical...
-
Episode 492: Novel Biomarkers and Targets in Germ Cell Tumors
This podcast features Dr. Mike Glover from MDACC discussing recent advances in germ cell tumor research, focusing on novel biomarkers like microRNA and ctDNA, and emerging therapies targeting Claudin-6. The conversation explores how these innovations could transform diagnosis, prognosis, and...
-
Episode 491 Uromigos Japan: ASCO GU26速報！前立腺がん&腎がん
前立腺がんはPEACE-3 final OSの結果について、腎がんはLITESPARK-011/022試験の解釈から実臨床への影響まで、現地での反応も含めて語り尽くします。
-
Episode 490: Systemic Therapy Only in Patients wtih MIBC
Laura Bukavina, Tyler Stewart and Amanda Nizam join Brian and Tom to discuss and debate a new clinical trial exploring EVP in MIBC with omission of cystectomy of clinical CR patients
-
Episode 489: Live Podcast From EAU
Tom and Brian take the stage in London for a live podcast. With the help of several special guests from the audience, they discuss management of peri-operative therapy in bladder cancer (notably in patients who may refuse cystectomy) and also the emerging pembro plus belzutifan data in adjuvant RCC.
-
Episode 488: Uromigos Japan - ASCO GU26速報！尿路上皮がん
周術期EV+PembroのKEYNOTE-B15試験をはじめとして、大きな話題が多かった今年のASCOGU。結果の解釈から今後の臨床への影響まで語り尽くします。
-
Episodio 485: ASCO GU 2026 - LITESPARK 011: Len/Belzutifan vs Cabo
En este episodio se abordan los resultados más recientes del ensayo fase 3 LITESPARK 011 (belzutifan + lenvatinib frente a cabozantinib). Brian, Tom y Bob Motzer analizan la eficacia, seguridad y las implicaciones de los resultados para la secuenciación de tratamiento.
-
Episodio 484: ASCO GU 2026 - LITESPARK 022: Pembro adyuvante + Belzutifan en cáncer renal
En esta discusión se exploran los últimos avances en el tratamiento adyuvante del cáncer de riñón, centrándose en los recientes resultados del ensayo fase 3 de belzutifan en combinación con pembrolizumab (LITESPARK-022). Se abordan los pormenores del mecanismo de acción, el desarrollo de...
-
Episodio 483: ASCO GU 2026 - KEYNOTE B15: EVP neoadyuvante vs Gem/Cis en cáncer de vejiga músculo-invasivo cisplatino elegible
En este episodio, Brian, Tom y Matt Galsky analizan los datos del estudio B15 sobre terapia neoadyuvante para el cáncer de vejiga músculo-invasivo cisplatino-elegible, centrándose en la eficacia de EV-Pembro en comparación con cisplatino-gemcitabina. Exploran la SLE, SG y las implicaciones de la...
-
Episodio 482: ASCO GU 2026 - SUNRISE 2
La conversación gira en torno al ensayo Sunrise 2, un estudio que investiga la eficacia de TAR-200 combinado con cetrilimab frente a quimiorradioterapia convencional en cáncer de vejiga músculo-invasivo. La discusión aborda el diseño del estudio, la población elegida, los resultados y las...
-
Episodio 480: ASCO GU 2026 - Resultados finales de SG de PEACE-3 y BRCAway
En este episodio, Evan Yu analiza los datos más recientes sobre cáncer de próstata presentados en ASCO GU, centrándose en los resultados finales de SG del ensayo PEACE-3, las implicaciones del cruce en las curvas de supervivencia y el papel de la terapia con radioligandos e inhibidores de PARP en...
-
Episode 487: ASCO GU 2026 recap
Brian, Silke and Tom discusses the latest data and insights from ASCO GU 2026 across kidney, prostate, and bladder cancer, highlighting new therapies, trial results, and future directions in urologic oncology.
-
Episode 486: ctDNA and utDNA Data in Peri-operative Urothelial cancer
summary This episode explores the latest advances in circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) in bladder cancer management. Experts discuss how these biomarkers are transforming perioperative decision-making, prognosis, and personalized treatment strategies.
-
Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo
This detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan plus Lenvatnib versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing.
-
Episode 484: ASCO GU 2026 - LITESPARK 022: Adjuvant Pembro + Belzutifan in RCC
This in-depth discussion explores the latest advancements in adjuvant kidney cancer treatment, focusing on the recent phase 3 trial results of belzutifan combined with Pembrolizumab (LITESPARK-022), mechanistic insights, biomarker development, and future research directions.
-
Episode 482: ASCO GU 2026 - SUNRISE 2
The conversation revolves around the Sunrise 2 trial, a study investigating the efficacy of TAR-200 combined with cetrilimab versus traditional chemoradiotherapy in muscle-invasive bladder cancer. The discussion covers the study's design, patient population, results, and implications for future...
-
Episode 483: ASCO GU 2026 - KEYNOTE B15: Neoadjuvant EVP vs Gem/Cis in Cis-eligible MIBC
In this podcast , Brian, Tom and Matt Galsky discuss the B15 study data on neoadjuvant therapy for muscle invasive bladder cancer, focusing on the efficacy of EV Pembro compared to gem-cis. They explore event-free survival, overall survival, and the implications of treatment duration and...
-
Episode 480: ASCO GU 2026 - PEACE-3 and BRCAway Final OS Results
In this episode, Evan Yu discusses the latest prostate cancer data presented at ASCO GU, focusing on the final overall survival results of the PEACE 3 trial, the implications of crossing survival curves, and the evolving role of radioligand therapy and PARP inhibitors in prostate cancer treatment.
-
Episode 479: Does the Timing of IO Infusion Impact Clinical Outcomes? A Critical Analysis
This episode critically examines a recent Nature Medicine paper on the timing of immune therapy infusion in lung cancer, exploring the scientific plausibility, methodological concerns, and implications for future research. Tom, Brian and David McDermott debate the validity of the findings, the...
-
Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria
Summary This Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the latest scientific evidence and clinical practices. The speakers discuss the new PCWG4 including new...
-
Episode 477: Uromigos Japan - GU Oncology 2025を総括!
3人で前立腺癌、腎癌、尿路上皮癌の2025をレビューしました。
-
Episode 476: ASCO GU 2026 Preview
In this podcast , the Uromigos discuss the upcoming ASCO GU conference. They delve into the latest research findings, including phase 3 trials, combination therapies, and the significance of biomarkers in treatment. The conversation highlights the importance of belzutifan in kidney cancer and...
-
Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis
In this Uromigos podcast episode, Brian and Tom engage with Elaine Chang from the FDA to discuss an analysis of depth of response as an indicator of survival in kidney cancer trials. They explore the FDA's data analysis process, the significance of tumor shrinkage, and the implications of their...
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
HOSTED BY
The Uromigos
Loading similar podcasts...
Frequently Asked Questions
How many episodes does The Uromigos have?
The Uromigos currently has 486 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is The Uromigos about?
Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary...
How often does The Uromigos release new episodes?
The Uromigos publishes regularly with 486 episodes available. Check the episode list for the typical release schedule.
Where can I listen to The Uromigos?
You can listen to The Uromigos on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts The Uromigos?
The Uromigos is created and hosted by The Uromigos.
URL copied to clipboard!